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Abstract
Background: Abnormal DNA methylation/demethylation is recognized as a hallmark of cancer. TET (ten-eleven
translocation) family members are novel DNA demethylation related proteins that dysregulate in multiple
malignances. However, their effects on ovarian cancer remain to be elucidated.
Methods: The changes of TET family members during TGF-β1-induced epithelial-mesenchymal transition (EMT) in
SKOV3 and 3AO ovarian cancer cells were detected. TET3 was ectopically expressed in TGF-β1-treated ovarian
cancer cells to examine its effect on TGF-β1-induced EMT phenotype. The downstream target of TET3 was further
identified. Finally, the relationships of TET3 expression to clinic-pathological parameters of ovarian cancer were
investigated with a tissue microarray using immunohistochemistry.
Results: TET3 was downregulated during TGF-β1-initiatd epithelial-mesenchymal transition (EMT) in SKOV3 and
3AO ovarian cancer cells. Overexpression of TET3 reversed TGF-β1-induced EMT phenotypes including the
expression pattern of molecular markers (E-cadherin, Vimentin, N-cadherin, Snail) and migratory and invasive
capabilities of ovarian cancer cells. miR-30d was identified as a downstream target of TET3, and TET3 overexpression
resumed the demethylation status in the promoter region of miR-30d precursor gene, resulting in restoration of
miR-30d (an EMT suppressor of ovarian cancer cells proven in our previous study) level in TGF-β1-induced EMT. We
further found that TET3 expression was decreased in ovarian cancer tissues, especially in serous ovarian cancers. The
overall positivity of TET3 was inversely correlated with the grade of differentiation status of ovarian cancer.
Conclusion: Our results revealed that TET3 acted as a suppressor of ovarian cancer by demethylating miR-30d
precursor gene promoter to block TGF-β1-induced EMT.
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Background
Ovarian cancer is the most lethal gynecological tumor
and ranks the fifth in the cause of death for women suf-
fered from tumor. It is estimated that there are 21,290
new ovarian cancer cases and 14,180 deaths in the
United States in 2015 [1]. The poor prognosis of ovarian
cancer patients is mainly attributed to cancer metastasis
and recurrence. Epithelial-mesenchymal transition (EMT)
is a dynamic process mediating ovarian cancer metastasis,
among others. Exploration of signaling pathways involved
in EMT process will shed light on the molecular mecha-
nisms of metastasis.
EMT refers to the transformation of epithelial cells
into fibroblast-like cells in physiological and pathological
processes, characterized by loss of epithelial markers, ac-
quisition of mesenchymal molecules and enhancement
of cell mobility [2]. Various cytokines and growth fac-
tors, including transforming growth factor β (TGF-β),
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are key agents for EMT initiation and maintenance.
Three isoforms of TGF-β are identified, and TGF-β1
is the most classical and frequently used EMT-
inducer [3, 4].
Increasing evidence shows that aberrations in DNA
methylation status are associated with tumor progression
and prognosis of patients [5]. DNA methyltransferases
(DNMTs) are major molecules controlling DNA methyla-
tion [6, 7]. Laterly, ten-eleven translocation (TET) family
members (TET1-3) which can modify 5-methylcytosine
(5-mC) by oxidation to 5-hydroxymethylcytosine (5-hmC)
and further 5-formylcytosine (5-fC) and 5-carboxycytosine
(5-caC) are identified and expand the understanding about
mechanisms of DNA demethylation [8–10]. TETs are
dysregulated in multiple malignances including breast
cancer [11], hepatocellular carcinoma [11], melanoma
[12] and glioma [13]. For example, decreased TET1
mRNA level is correlated with poor survival of breast
cancer patients [14], and the same goes for TET2 in
colorectal cancer [15].
Aberrant DNA methylation/demethylation is impli-
cated in TGF-β1-induced EMT [16–18]. TGF-β1 triggers
TIP30 (gene coding HIV-1 Tat interactive protein 2)
hypermethylation by upregulating DNMT1 and DNMT3A
to induce EMT and metastasis in esophageal carcinoma
[19]. However, few researches are performed to elaborate
the role of TETs in TGF-β1-induced EMT. Here we report
the epigenetic regulation of TET3 on miR-30d in TGF-
β1-induced EMT in ovarian cancer cells, highlighting
the potentiality of TET3 to be used as a prognostic bio-
marker or a therapeutic target for ovarian cancer.
Methods
Cell culture and TGF-β1 treatment
Human ovarian cancer cell line SKOV3 was obtained
from the Shanghai Cell Bank of Chinese Academy of
Sciences (Shanghai, China), and 3AO was from the
Shandong Academy of Medical Sciences (Jinan, China).
Cells were incubated in RPMI 1640 (GIBCO, Grand
Island, NY USA) supplemented with 10 % newborn bovine
serum (GIBCO, Grand Island, NY, USA) at 37 °C in 5 %
CO2. When treated with 10 ng/ml TGF-β1 (PeproTech,
Rocky Hill, USA), cells were maintained in media contain-
ing 1 % newborn bovine serum for indicated time before
harvested.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol re-
agent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Concentration and quality
of total RNA were assessed by absorbance at 260 nm
and the ratio of 260/280, respectively, on a UV spectro-
photometer (BioRad Inc., Hercules, CA, USA). For
mRNA detection, first-strand cDNA was synthesized
using a PrimeScript™ RT reagent Kit with gDNA Eraser
(Takara, Dalian, China). Quantitative real-time PCR was
performed using a SYBR Premix Ex Taq™ II kit (Takara,
Dalian, China) on a CFX96 real-time PCR system
(Bio- Rad, Hercules, CA, USA). TET1, TET2 and TET3
were normalized to β-actin, while miR-30s were normal-
ized to small nuclear U6. Relative gene expression was
calculated automatically using 2-ΔΔCt. PCR primers for
TET1, TET2, TET3 and β-actin were synthesized by
Beijing Genomics Institute (Beijing, China), and primer
sequences were listed in Table 1. Primers for miR-30a,
30b, 30c, 30d, 30e, and U6 reverse transcription and amp-
lification were designed and synthesized by Ribo-Bio Co.,
Ltd. (Guangzhou, China).
Western blot
Total protein was collected from cells by RIPA lysis buf-
fer containing protease inhibitors (Roche, Indianapolis,
IN, USA) and 1 mM PMSF on ice. Protein concentration
was measured using the BCA-200 Protein Assay kit
(Pierce, Rockford, IL, USA). After heat denaturation at
100 °C for 5 min, proteins were separated by electro-
phoresis on 10 % SDS–PAGE gels and then transferred
onto nitrocellulose membranes (Pall Life Science, Port
Washington, NY, USA). The membranes were blocked
with 5 % non-fat milk at room temperature for 1 h, and
then incubated overnight at 4 °C with rabbit anti-
human TET3 (Abcam, 1:1000), E-cadherin (Cell Signal-
ing Technology (CST, 1:1000), Vimentin (CST, 1:500),
N-cadherin (CST, 1:1000), Snail (CST, 1:300) and mouse
anti-human β-actin (CST, 1:1000). After washing with
TBST, the blots were incubated with horse radish perox-
idase (HRP)-conjugated goat anti-rabbit or anti-mouse
IgG. Blots were visualized using ECL reagents (Pierce,
Rockford, IL, USA) by a chemiluminescence imaging
system (Bio-Rad, Richmond, CA, USA). The results
were quantified by Image J software.
Plasmid transient transfection
The human TET3 expression vector FH-TET3-pEF was
obtained from Addgene. SKOV3 and 3AO cells were
Table 1 Primer sequences for real-time PCR
Genes primer sequences (5′-3′) Length of PCR product (bp)
TET1 F: CCCGAATCAAGCGGAAGAATA 101
R: TACTTCAGGTTGCACGGT
TET2 F: CTTTCCTCCCTGGAGAACAGCTC 146
R: TGCTGGGACTGCTGCATGACT
TET3 F: GTTCCTGGAGCATGTACTTC 93
R: CTTCCTCTTTGGGATTGTCC
β-actin F: TCCCTGGAGAAGAGCTACGA 194
R: AGCACTGTGTTGGCGTACAG
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seeded into 6-well plates until 70 %-80 % confluence and
transiently transfected with FH-TET3-pEF or empty vec-
tor using the X-treme GENE HP DNA Transfection Re-
agent (Roche, Indianapolis, IN, USA).
miR transient transfection
miR-30d mimic and negative control were purchased
from Ribo-Bio Co. Ltd. (Guangzhou, China). SKOV3
and 3AO cells were seeded into 6-well plates to reach
40 %–50 % confluence after 24 h and then transiently
transfected with 100 nM miR-30d mimic or negative
control using the X-treme GENE siRNA Transfection
Reagent (Roche, Indianapolis, IN, USA). After 24 h of
transfection, the cells were treated with 10 ng/ml TGF-
β1 for another 48 h.
Cell migration and invasion assay
After transient transfection of FH-TET3-pEF or empty
vector and treatment of TGF-β1 for 48 h, cells were
trypsinized and counted. A total of 1 × 105 cells (for mi-
gration assay) or 4 × 105 cells (for invasion assay) in
100 μl serum-free medium was added into millicells
(Millipore Co., Bedford, MA, USA) without (for migra-
tion assay) or with (for invasion assay) Matrigel (Becton
Dickinson Labware, Bedford, MA, USA) coated. 500 μl
of medium containing 20 % newborn bovine serum was
added into the bottom chambers as the chemotactic fac-
tor. After incubation for 24 h (for migration assay) or
48 h (for invasion assay) at 37 °C in 5 % CO2, cells
remaining on the upper surface of the filter were re-
moved using cotton swabs. Then the migrated cells were
fixed using methyl alcohol and stained using 0.1 % crys-
tal violet. Migratory (or invasive) cells were counted and
averaged from images of five random fields (original
magnification × 200) captured using an inverted light
microscope. The mean values of three duplicate assays
were used for statistical analysis.
DNA bisulfite modification and methylation-specific PCR
(MSP)
Cells treated by 10 ng/ml TGF-β1 for 48 h in 24-well
plates were resuspended with cold PBS for ~6 × 106/ml.
DNA bisulfite modification and purification were per-
formed using an EZ DNA methylation-Direct kit (Zymo
Fig. 1 TET3 was downregulated in TGF-β1-treated ovarian cancer cells. SKOV3 and 3AO cells were maintained in 1640 medium containing 1 %
newborn bovine serum with or without 10 ng/ml TGF-β1 for 48 h. a Quantitative real-time PCR showed that TET3 was significantly decreased at
mRNA level in cells treated by TGF-β1, and TET1 was also downregulated in TGF-β1-treated SKOV3 cells. b Western blot results and (c) the quantitative
analysis revealed that TET3 protein was decreased in cells stimulated by TGF-β1. All experiments were carried out in triplicate and the results were
presented as means ± SD. *P < 0.05, **P < 0.01, t-test
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Research Corporation, Irvine, California, USA) according
to the instruction. Concentration of DNA was evaluated
by absorbance at 260 nm on a UV spectrophotometer
(BioRad Inc., Hercules, CA, USA). The set of primers
for miR-30d gene was flanking the 3 kb region of the 5′
upstream region from the start of pre-miR-30d se-
quence. The primers for methylation-specific PCR were
designed by MethPrimer and the sequences were as fol-
lows: methylated (M)-forward (F): 5′-TTGAGATAGG
GTTTTATTTTGTCGT-3′; methylated (M)-reverse (R):
5′-TAATACATACGATCCCAACTATTCG-3′;unmethy-
lated (U)- forward (F): 5′-TGAGATAGGGTTTTAT
TTTGTTGT-3′; unmethylated (U)- reverse (R): 5′-ATAC
ATACAATCCCAACTATTCAAA-3′. DNA amplification
was performed with Epi Taq HS (Takara Biotechnology
Co. Ltd., Dalian, China) under the following condition:
94 °C for 5 min; 30 cycles of 94 °C for 30 s, 50 °C for
30 s, 72 °C for 30 s; and 72 °C for 10 min. The PCR
products were separated by 2.0 % agarose gel electro-
phoresis and visualized by a chemiluminescence im-
aging system (Bio-Rad, Richmond, CA, USA).
Immunohistochemistry
Human ovarian cancer tissue microarray was purchased
from Shanghai SuperChip Biotech Co. Ltd. (Shanghai,
China) and rabbit antibody to TET3 used for immuno-
histochemistry was purchased from Genetex (Alton
PkwyIrvine, CA, USA). The tissue array was dewaxed in
Fig. 2 Overexpression of TET3 reversed TGF-β1-induced EMT in ovarian cancer cells. Cells were exposed to negative control, negative control plus
TGF-β1 and FH-TET3-pEF transiently transfection plus TGF-β1, respectively. a Quantitative real-time PCR showed that transfection of FH-TET3-pEF
rescued TET3 mRNA level in TGF-β1-treated cells. b Western blot results and (c) the quantitative analysis indicated that transfection of FH-TET3-pEF
rescued TET3 protein level in TGF-β1-treated cells. Meanwhile, E-cadherin decrease and N-cadherin, Vimentin and Snail increase caused by TGF-β1 were
reversed by TET3 overexpression. All experiments were carried out in triplicate and the values were showed as means ± SD. *P < 0.05, **P < 0.01, t-test
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xylene, rehydrated in a descending alcohol series.
Antigen retrieval was performed by heating the tissue
section in 0.01 M citrate buffer (pH 6.0) in a steamer
for 90 s. Detection of antigen was carried out through
incubation with anti-TET3 antibody (1:250) for 2 h at
room temperature, followed by incubation with HRP-
labeled secondary antibody at room temperature for
30 min. Signal was generated by incubation with DAB.
Slide was counterstained with hematoxylin, dehy-
drated in an ascending alcohol series, and mounted
for analysis. Digital images were acquired using a
section microscope scanner (Leica MP SCN400,
German). Membrane, cytoplasm or nuclear staining
was considered positive for TET3. For statistical ana-
lysis, extent (the percentage of positive cells) and in-
tensity of staining were obtained by 2 pathologists.
Intensity was semiquantitatively scored as weak (1
point), moderate (2 points), or strong (3 points). For
an individual case, the immunohistochemical compos-
ite score was calculated based on the extent multiplied
by the intensity score.
Statistical analysis
The graphical presentations were performed using
GraphPad Prism 5.0. Data were presented as the
means ± SD and were analyzed using SPSS 22.0 soft-
ware (Chicago, IL, USA). Statistical differences were
tested by Chi-square test, two-tailed t-test, one-way
ANOVA test or Fisher’s Exact test. Differences were
considered significant at P <0.05 (*) or highly signifi-
cant at P <0.001 (**).
Results
TET3 was reduced in TGF-β1-treated ovarian cancer cells
We first examined the expression of TET family mem-
bers in TGF-β1-treated ovarian cancer cells. As shown
by qRT-PCR results (Fig. 1a), TET1 and TET3 were
downregulated while TET2 was remained unchanged in
SKOV3 and 3AO cells treated by TGF-β1. And the most
significant TGF-β1-induced reduction was seen in TET3
mRNA in both cells. TET3 protein level was then de-
tected, and consist with mRNA reduction, TET3 protein
was decreased in TGF-β1-stimulated ovarian cancer cells
Fig. 3 Overexpression of TET3 antagonized TGF-β1-enhanced motility and invasion of ovarian cancer cells. a In vitro migration assay showed that
cell motility was promoted when exposed to TGF-β1, which was inhibited by TET3 overexpression (original magnification × 200). b In vitro invasion
assay showed that TET3 overexpression quenched stimulation effect of TGF-β1 on cell invasion (original magnification × 200). All experiments were
performed in triplicate and data were showed as means ± SD. *P < 0.05, **P < 0.01, t-test
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(Fig. 1b and c), indicating the potential involvement of
TET3 in TGF-β1 signaling.
TET3 overexpression reversed TGF-β1-triggered EMT in
ovarian cancer cells
Since TGF-β1 could induce EMT in ovarian cancer cells
in our previous study [20], we speculated that TET3
might participate in TGF-β1-triggered EMT. To test this
possibility, FH-TET3-pEF was transfected into TGF-β1-
treated cells to resume the expression of TET3 (Fig. 2a).
For the record, since the recombinant FH-TET3-pEF
plasmid contained no fluorescence tag, the transfection
efficiency was evaluated by TET3 level in TET3-
transfected cells relative to negative control cells using
Fig. 4 TET3 was an upstream regulator of miR-30d. a Quantitative real-time PCR showed that decreased miR-30s by TGF-β1 was reversed by
restoration of TET3 both in SKOV3 and 3AO cells. b Western blot results and (c) the quantitative analysis indicated that resume of miR-30d could
not reverse the downregulation of TET3 induced by TGF-β1 in ovarian cancer cells. d MSP assay proved that methylation of miR-30d precursor
gene was increased in TGF-β1-treated cells. e Quantitative analysis of MSP results showed that methylated proportion of miR-30d precursor gene
in FH-TET3-pEF transfected and TGF-β1 co-treated cells was lower than TGF-β1-treated cells. *P < 0.05, **P < 0.01, t-test
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real-time PCR and western blot (Additional file 1: Figure
S1A and S1B). Restoration of TET3 antagonized TGF-
β1-triggered EMT as illustrated by reversion of E-
cadherin downregulation and N-cadherin, Vimentin, and
Snail upregulation (Fig. 2b and c). In parallel, TET3 recov-
ery greatly counteracted TGF-β1-stimulated enhancement
of migration (Fig. 3a) and invasion (Fig. 3b) of both
SKOV3 and 3AO cells. Taken together, these results
showed that TET3 was a negative regulator of TGF-β1-
induced EMT in ovarian cancer cells.
TET3 upregulated miR-30d to inhibit TGF-β1-induced EMT
in ovarian cancer cells
We previously found that miR-30 family members were
downregulated in TGF-β1-treated ovarian cancer cells
and restoration of miR-30d blocked TGF-β1-induced
EMT [20]. We supposed that TET3 might oppose TGF-
β1-induced EMT by increasing miR-30d. Consistent
with our supposition, overexpression of TET3 resumed
TGF-β1-downregulated miR-30s (Fig. 4a). In addition,
co-treatment of miR-30d mimic could not reverse TGF-
β1-rendered TET3 decrease (Fig. 4b and c), indicating
TET3 was an upstream regulator of miR-30d, not vice
versa. The MSP assay further verified that methylation
of miR-30d precursor gene was increased in TGF-β1-
treated cells (Fig. 4d), which was abrogated by overexpres-
sion of TET3 (Fig. 4e). Of note, TET3 overexpression alone
could increase expression level of miR-30d and decrease
methylation level of miR-30d precursor gene (Additional
file 2: Figure S2A and S2B). These data demonstrated that
TGF-β1-decreased TET3 contributed to higher methyla-
tion level of miR-30d precursor gene, subsequently caused
miR-30d downregulation in ovarian cancer cells.
TET3 was decreased in ovarian cancer tissues and
negatively correlated with pathological grade
We further assessed TET3 expression with a human
ovarian cancer tissue microarray, and finally obtained
TET3 protein status in 67 ovarian cancer samples and
14 normal ovarian samples. TET3 mainly located in
cytoplasm of both normal and tumor cells (Fig. 5). To
quantify the differential TET3 expression among differ-
ent subgroups, a semiquantitative scoring system was in-
troduced by multiplying the positive extent with the
intensity score. No significant difference in the overall
positivity of TET3 was found between normal and can-
cerous tissues (P = 0.724). However, the immunohisto-
chemical composite scores of cancer samples was lower
than that of normal tissues (P = 0.0269) (Table 2). TET3
expression level in various histopathological subtypes of
ovarian cancer was further analyzed. As Table 2 shown,
the average score for serous ovarian cancer was signifi-
cantly lower than that for normal tissues (P = 0.0401), while
no statistic differences were found between normal tissues
and other subtypes of ovarian cancer. Clinicopathological
correlation analysis of TET3 level to ovarian cancer
showed that the overall positivity of TET3 was inversely
associated with the grade of differentiation of malignant
cells (P = 0.024). Although no significant differences of im-
munohistochemical composite score were found among
different differentiation status, the poorest differentiated
tissues presented with lowest immunohistochemical score
(P = 0.2409) (Table 3).
Discussion
With the deepening of studies about epigenetics and
tumorigenesis, it has been admitted that abnormal DNA
Fig. 5 Immunostaining of TET3 in normal ovarian tissue and serous ovarian cancer. The representative photographs were taken using a section
microscope scanner at 40× and 400×. a Moderate immunostaining of TET3 in cytoplasm of normal ovarian tissue. b Weak immunostaining of
TET3 in cytoplasm of well differentiated serous ovarian cancer. c Weak positivity of TET3 in cytoplasm of moderately differentiated serous ovarian
cancer. d Weak to negative positive staining of TET3 in cytoplasm of poorly differentiated ovarian cancer tissue
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methylation/demethylation is a hallmark of cancer [21].
In addition to DNMTs, TETs are novel regulators of
DNA methylation/demethylation status. Growing evi-
dences suggest that deregulation of TETs and TET-
mediated DNA demethylation takes part in tumor
development and progression [14, 22–25].
In our study, we found that TET3 was decreased in
ovarian cancer tissues, as well as in TGF-β1-treated ovar-
ian cancer cells. Loss of TET3 might result in poorer
histopathological grade in ovarian cancer patients. It was
reported that TET3 was reduced in TGF-β1-activated hu-
man hepatic stellate cells (LX-2 cells), which played a crit-
ical role in liver fibrosis. Silencing of TET3 inhibited
apoptosis, promoted proliferation and induced cell fibrosis
in LX-2 cells by downregulating long non-coding RNA
(lncRNA) HIF1A-AS1 [26]. In our experiments, TGF-β1
reduced TET3 in human ovarian cancer cells, and TET3
overexpression blocked TGF-β1-induced EMT via resum-
ing the demethylation status of pre-miR-30d promoter re-
gion. As fibrosis was also closely connected to EMT, we
speculated that TET3 could be a suppressor of EMT func-
tioning in different tissues and EMT-associated events. In
both studies, TET1 and TET2 remained almost un-
changed during TGF-β1 stimulation. It might be attrib-
uted to tissue or cell specificity. Preview studies indicated
that TET1 and TET2 mainly acted in embryonic stem
cells (ESCs), induced pluripotent stem cells (iPSCs) and
primordial germ cells (PGCs) [27–29], while TET3 was
the only member identified in mouse oocytes and one-cell
zygotes [30]. Although the expression pattern of TETs
changed during development, differences still existed in
diverse tissues and cells.
Our findings indicated that reduction of TET3 could
be a result of TGF-β1 stimulation. To date, it was unclear
how TGF-β1 decreased TET3. Recent studies showed that
TETs were direct targets of multiple microRNAs (miRs),
suggesting the proteins to be post-transcriptionally regu-
lated by miRs [31]. miR-26, implicated in various cancers
as an oncogene or tumor suppressor [32, 33], could de-
crease expression of all members of the TET family in ver-
tebrates [34]. Another example was miR-29 that directly
targeted TET1 in lung cancer cells [35], and all TET fam-
ily members in human dermal fibroblasts and vascular
smooth muscle cells [36]. Interestingly, miR-29 was a crit-
ical mediator in TGF-β/Smad signaling [37]. Thus, we
presumed that TET3 reduction in our model could be a
result of miR dysregulation. Nevertheless, TET3 could be
also controlled by DNA methylation/demethylation, as
found in clinical samples [15]. Illumination of the









P value Mean SD P value
Ageb
< 50 (n = 25) 17 (68 %) 0.3793 0.65 0.77 0.9822
≥ 50 (n = 39) 31 (78.5 %) 0.66 0.62
NA (n = 4)
Gradec
G1 (n = 7) 7 (100 %) 0.024* 0.73 0.50 0.2409
G2 (n = 26) 23 (88.5 %) 0.93 0.76
G3 (n = 29) 18 (62.1 %) 0.59 0.76
aPercentage of cases with more than 5 % positive cells. bFisher’s Exact Test
(two-tailed). ct-test or one-way ANOVA (two-tailed). NA non-available
* P < 0.05
Table 2 Positivity and composite scores of TET3 in ovarian cancer tissues
Immunohistochemical composite scores
Subtypes of ovarian cancer Overall Positivitya P valueb Mean SD P valuec
Normal (n = 14) 12 (85.7 %) 1.21 0.90
Ca (n = 68) 52 (76.5 %) 0.724 0.72 0.72 0.0269*
EOC
Serous cancer (n = 37) 29 (78.4 %) 0.707 0.71 0.70 0.0401*
Mucinous cancer (n = 8) 8 (100 %) 0.515 1.16 0.78 0.8932
Endometrioid cancer (n = 5) 4 (80 %) 1.000 1.10 1.06 0.8182
Clear cell cancer (n = 5) 5 (100 %) 1.000 0.86 0.67 0.4345
Germ cell tumor
Dysgerminomas (n = 3) 1 (33.3 %) 0.121 0.10 0.17 0.0541
Endodermal sinus tumor (n = 1) 0
Immaure teratomas (n = 2) 1 (50.0 %) 0.350 0.40 0.56 0.2402
Granulosa cell tumor (n = 3) 2 (66.7 %) 0.456 0.40 0.35 0.1508
aPercentage of cases with more than 5 % positive cells. bFisher’s Exact Test (two-tailed), compared with the positive percentage of normal tissues. ct-test (two-tailed),
compared with the composite scores of normal cases. * P < 0.05
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molecular underpinnings of TGF-β-induced TET3 reduc-
tion would contribute to understanding the regulatory
network in TGF-β-stimulated EMT.
Conclusions
Our results indicated that TET3 declined in TGF-β1
stimulation and TET3 overexpression inhibited TGF-β1-
induced EMT and EMT-mediated metastasis of SKOV3
and 3AO cells by demethylating miR-30d precursor gene,
indicating a novel mechanism of epigenetic regulation in
ovarian cancer. Targeting the TGF-β1-TET3-miR-30d sig-
naling axis might be a promising therapeutic strategy for
ovarian cancer treatment.
Additional files
Additional file 1: Figure S1. Transfection efficiency of recombinant
expression plasmid for TET3. a Quantitative real-time PCR showed that
TET3 was increased by about 100 times in TET3-transfected SKOV3 cells
relative to negative control cells. b Western blot results and the quantitative
analysis revealed that TET3 protein was increased by about 3 times in
TET3-transfected SKOV3 cells relative to negative control cells. All experiments
were carried out in triplicate and the results were presented as means ± SD.
*P < 0.05, t-test. (JPG 132 kb)
Additional file 2: Figure S2. The effect of TET3 overexpression on
miR-30d. a Quantitative real-time PCR showed that miR-30d was increased
by ectopic expression of TET3 in SKOV3 cells. b MSP assay found that
methylation of miR-30d precursor gene was decreased in TET3-overexpressed
SKOV3 cells. (JPG 123 kb)
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